On July 27, AstraZeneca PLC rose 5.33% overnight, trading at $178.29/share, with turnover of $251,700.

On the news front, AstraZeneca PLC reported second-quarter results with core earnings per share of $2.63, significantly exceeding the consensus estimate of $2.48, representing an approximately 6% beat. The market had previously expected adjusted EPS of $2.54, implying year-over-year growth of roughly 18%, and the actual result surpassed even the most optimistic forecasts.

Notably, AstraZeneca PLC shares had been under pressure after its Wainua heart disease drug failed a Phase 3 trial in early July, causing a single-day decline of nearly 9% and bringing the year-to-date loss to approximately 10%. The earnings beat helps alleviate investor concerns over the company's pipeline execution capability. Market attention now shifts to upcoming late-stage oncology trial results from SERENA-4 and AVANZAR, which could further shape confidence in AstraZeneca PLC's long-term growth trajectory toward its stated goal of $80 billion in annual revenue by 2030.

(The above content is based on publicly available market information, generated by a program or algorithm, and is intended solely as a stock movement alert. It does not constitute investment advice or a basis for trading decisions.)